 |
2 Diseases |  |
12 Trials |
|
12 Trials |  |
490 News |  |
| «123456» |
- | Journal: Therapeutic Strategies for Neuromyelitis Optica (Pubmed Central) - May 21, 2023
Recently, biologic agents such as eculizumab, satralizumab, inebilizumab, and rituximab have been approved for use in Japan. Although side effects caused by steroid therapy have been issues for patients in the past, active use of the newly approved biologics is expected to help patients avoid the adverse effects of steroids and improve their qualities of life.
- | Enspryng (satralizumab) / Roche
Journal: Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report. (Pubmed Central) - May 19, 2023
Although side effects caused by steroid therapy have been issues for patients in the past, active use of the newly approved biologics is expected to help patients avoid the adverse effects of steroids and improve their qualities of life. No abstract available
- || Retrospective data, Review: Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. (Pubmed Central) - Apr 21, 2023
The off-label mAbs may be used as the first-line treatment for improving clinical outcomes including disease relapse, ARR, and SAEs for NMOSD in countries where resources and accessibility of the FDA-approved mAbs are limited. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=283424, identifier: CRD42021283424.
- || Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Review, Journal: Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. (Pubmed Central) - Mar 25, 2023
Only satralizumab has recruited adolescents in one of the two pivotal clinical trials. Additional clinical trials in pediatric NMOSD are urgently required to evaluate the safety and efficacy of these drugs in this population.
- | Enspryng (satralizumab) / Roche
Journal: Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. (Pubmed Central) - Mar 16, 2023
Using an IL-6 inhibitor agent to prevent dTAA formation and progression showed promising results. It suggests that using the IL-6 inhibitors in susceptible persons can be considered a lifesaving therapeutic approach.
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
High-Efficacy Therapies Reduce Clinical and Radiological Events More Effectively than Traditional Treatments in Neuromyelitis Optica Spectrum Disorder (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4423;
A 15-fold increase in the odds of MRI advancement involving the spinal cord (95% credible interval=[2.34, 287.15]) was observed during treatment with a traditional medication versus with a high-efficacy agent. Conclusions The availability of newer treatments maximizes the opportunity to reduce permanent neurological disability over traditionally used medications in both newly diagnosed and established people with NMOSD.
- Enspryng (satralizumab) / Roche
Satralizumab Treatment in Adult Patients With AQP4-IgG (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4064;
Conclusions In this ongoing retrospective case series, patients with NMOSD receiving satralizumab either as monotherapy or in combination with immunosuppressants in clinical practice had a beneficial response compared with previous treatments, and satralizumab was well tolerated. These outcomes align with the efficacy and safety outcomes with satralizumab in Phase 3 SAkura clinical trials.
- Enspryng (satralizumab) / Roche
Long-term Safety of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_4056;
P3
These outcomes align with the efficacy and safety outcomes with satralizumab in Phase 3 SAkura clinical trials. Conclusions These results demonstrate that the safety of satralizumab (
- Enspryng (satralizumab) / Roche
Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_1575;
P3
Conclusions These results demonstrate that the efficacy of satralizumab observed in the DBPs is sustained with long-term treatment. High proportions of patients remained free from relapse, severe relapse, or worsening disability, with a consistently low ARR over 4.6 years of satralizumab exposure.
- || Retrospective data, Review, Journal: Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. (Pubmed Central) - Mar 9, 2023
For safety, MMF and RTX had fewer AEs. However, studies with larger sample size on newly developed monoclonal antibodies are warranted in the future.
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Cost-Effectiveness of the First-Line Treatments for Neuromyelitis Optica Spectrum Disorder (NMOSD) in Adult Patients in China () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2354;
However, studies with larger sample size on newly developed monoclonal antibodies are warranted in the future. Inebilizumab may be the most cost-effective option to prevent relapse compared to Satralizumab and Rituximab in adult NMOSD patients in China.
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe
Modelling the Long-Term Effectiveness of Inebilizumab in the Current Treatment Landscape of NMOSD () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1870;
The results suggest that treatment with inebilizumab is associated with an increase in LYs and QALYs compared to eculizumab, satralizumab and rituximab. Relative efficacy and discontinuation were the key drivers of the results.
- || Enspryng (satralizumab) / Roche
New P1 trial: SASH: Satralizumab in Aneurysmal Subarachnoid Hemorrhage (clinicaltrials.gov) - Feb 14, 2023
P1, N=15, Not yet recruiting, Sponsor: University of Florida
Relative efficacy and discontinuation were the key drivers of the results. .
- ||| Enspryng (satralizumab) / Roche
Trial completion date, Trial primary completion date, Monotherapy: Meteoroid: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (clinicaltrials.gov) - Feb 8, 2023
P3, N=152, Recruiting, Sponsor: Hoffmann-La Roche
. Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Oct 2025 --> Apr 2026
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Enspryng (satralizumab) / Roche
Clinical, Journal: Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies. (Pubmed Central) - Feb 7, 2023
Despite being lower than in healthy controls, the humoral vaccine response during anti-IL-6 receptor therapy was evident in all patients and substantially stronger compared to anti-CD20 treatment. No relevant disease activity occurred after mRNA vaccination against SARS-CoV-2.
- Enspryng (satralizumab) / Roche
Satralizumab Treatment in Adult Patients With AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder Switching From Other Therapies: A Case Series (Pacific Ballroom) - Feb 7, 2023 - Abstract #ACTRIMSForum2023ACTRIMS_Forum_221;
No relevant disease activity occurred after mRNA vaccination against SARS-CoV-2. Abstract is embargoed at this time.
- Enspryng (satralizumab) / Roche
Long-term Efficacy and Safety of Satralizumab in Adults with AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Roll-over, Open-label Study SAkuraMoon (Pacific Ballroom) - Feb 7, 2023 - Abstract #ACTRIMSForum2023ACTRIMS_Forum_214;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- | Enspryng (satralizumab) / Roche
Journal: Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. (Pubmed Central) - Feb 2, 2023
P3
These long-term results from the OLE periods of the SAkura studies demonstrate the continued efficacy of satralizumab over more than 3.5 years of treatment. High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR.
- || Enspryng (satralizumab) / Roche
Biomarker, Trial completion date, Trial primary completion date: SAkuraBonsai: A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (clinicaltrials.gov) - Jan 17, 2023
P4, N=100, Recruiting, Sponsor: Hoffmann-La Roche
High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR. Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Jul 2025 --> May 2026
- | Enspryng (satralizumab) / Roche
New P2 trial: Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) (clinicaltrials.gov) - Jan 11, 2023
P2, N=24, Recruiting, Sponsor: International University of Health and Welfare
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
SS4. Industry Supported Satellite Symposium 4: A Deeper Look at Neuromyelitis Optica Spectrum Disorder: A Glimpse Onto the Clinic Floor with Specialists (Marriott Marquis San Diego Marina) - Jan 10, 2023 - Abstract #ACTRIMSForum2023ACTRIMS_Forum_71;
Target Audience The target audience for this CME initiative includes neurodegenerative disease specialists, general neurologists, advanced practice neurology professionals, and other healthcare professionals involved in the diagnosis and long-term management of patients with NMOSD. Learning Objectives Upon completion of the educational activity, participants should be able to: Compare and contrast your diagnostic and management approaches for patients with diverse presentations of NMOSD to those of specialists and affirm or modify your decision-making accordingly Distinguish key clinical and radiological features that distinguish NMOSD alongside rising tools for prognosis in order to more rapidly diagnose and tailor clinical strategies to individuals with both AQP4-IgG seropositive and seronegative presentations of the disease Assess clinical investigator perspectives on the optimal management of acute attacks, including appropriate corticosteroid and plasma exchange protocols, and subsequent follow-up in order to maximize acute recovery and formulate effective management plans long term Describe the roles of, most recent data evaluating, and clinical experience utilizing agents specifically designed to treat NMOSD to integrate them more effectively into practice and maximize patient outcomes
- | Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases. (Pubmed Central) - Dec 16, 2022
In Chile, patients with MOGAD exhibit a wide spectrum of clinical presentations at disease onset and during relapses. Close monitoring is needed, particularly in younger patients with short follow-up periods.
- Enspryng (satralizumab) / Roche
Trial initiation date: SAkuraSun: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) (clinicaltrials.gov) - Dec 2, 2022
P3, N=8, Recruiting, Sponsor: Hoffmann-La Roche
Close monitoring is needed, particularly in younger patients with short follow-up periods. Initiation date: Nov 2022 --> Feb 2023
- | Enspryng (satralizumab) / Roche
Journal: Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient. (Pubmed Central) - Nov 29, 2022
Analytic control for satralizumab is recommended at 4 weeks. However, we recommend this control at week 2, in order to closely monitor neutrophil count and prevent further complications.
- | Enspryng (satralizumab) / Roche
Journal: Severe febrile neutropenia associated with satralizumab in an Argentinian NMOSD patient-Commentary. (Pubmed Central) - Nov 29, 2022
However, we recommend this control at week 2, in order to closely monitor neutrophil count and prevent further complications. No abstract available
- | Journal: An update on biologic treatments for neuromyelitis optica spectrum disorder. (Pubmed Central) - Nov 23, 2022
Effective rescue therapy for acute attack is critical given permanent disability in NMOSD is attack-related, and biologic agents that treat acute attack are emerging. If such treatments are to become widely applied, studies on the most cost-effective treatment strategies are needed.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Enspryng (satralizumab) / Roche
Review, Journal: Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. (Pubmed Central) - Nov 18, 2022
Among these, tocilizumab and satralizumab, humanized monoclonal antibodies against the IL-6 receptor, have shown beneficial effects in the treatment of this group of diseases. In this review, we summarize current research progress and prospects relating to anti-IL-6 therapies in CNS IDDs.
- | Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Journal: A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder. (Pubmed Central) - Nov 10, 2022
In this review, we summarize current research progress and prospects relating to anti-IL-6 therapies in CNS IDDs. No abstract available
- || Sylvant (siltuximab) / Jazz, Actemra IV (tocilizumab) / Roche, JW Pharma, Enspryng (satralizumab) / Roche
Review, Journal: A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. (Pubmed Central) - Oct 26, 2022
No abstract available IL-6 inhibition is effective for treatment of several inflammatory diseases with a safety profile that is widely comparable to other bDMARDs.
- | Enspryng (satralizumab) / Roche
Journal: Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. (Pubmed Central) - Oct 20, 2022
P3
IL-6 inhibition is effective for treatment of several inflammatory diseases with a safety profile that is widely comparable to other bDMARDs. The safety profile of satralizumab as a monotherapy or in combination with IST was maintained in the OLE, and no new safety concerns versus the DB period were observed.
- || Retrospective data, Review, Journal: Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. (Pubmed Central) - Oct 20, 2022
However, physicians should pay attention to its serious complications. The diversity of results from the published trials on the efficacy and safety of AHSCT calls for further investigations on determining the ideal AHSCT conditioning and the characteristics of patients.
- || Review, Journal: What's new in neuromyelitis optica spectrum disorder treatment? (Pubmed Central) - Oct 18, 2022
These monoclonal antibodies are directed against the complement system, CD19 B-cells and the IL6 receptor, respectively. All three have been approved for NMOSD in the US and several other countries worldwide and thus provide convincing treatment options.
- Enspryng (satralizumab) / Roche
METEOROID: A Randomised, Double-Blind, Placebo-controlled, Multicentre Phase 3 Study of Satralizumab in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1506;
P3
Patients refractory to azathioprine (AZA) or mycophenolate mofetil (MMF) may maintain a stable dose of AZA or MMF throughout. METEOROID is the first study of satralizumab in MOGAD, providing efficacy, safety, and PK/PD data for satralizumab ± IST in patients with MOGAD.
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Enspryng (satralizumab) / Roche
Efficacy Comparison of Time to First Adjudicated Attack with Inebilizumab vs Satralizumab in NMOSD: a Matching-Adjusted Indirect Comparison of Monotherapy Registrational Trials (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_906;
P2/3, P3
METEOROID is the first study of satralizumab in MOGAD, providing efficacy, safety, and PK/PD data for satralizumab ± IST in patients with MOGAD. While cross-study comparisons have limitations, these results suggest a meaningful efficacy advantage of inebilizumab over satralizumab for the prevention of NMOSD attacks.
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Long-term Burden of Attacks in Patients With AQP4+ NMOSD: A Simulation Study Based on Results of a Network Meta-analysis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_900;
Based on this Markov model, which extrapolated the results of a prior NMA, eculizumab was associated with the longest attack-free time compared with satralizumab or inebilizumab. Patients receiving eculizumab were also projected to experience the highest number of additional QALYs.
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
International, evidence-based Delphi consensus on the management of AQP4-IgG seropositive NMOSD, with a focus on treatment recommendations for eculizumab, inebilizumab and satralizumab (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_892;
An established consensus method was used to develop statements on the most pertinent areas of AQP4-IgG seropositive NMOSD management. These international statements will be valuable for informing decision-making that optimizes patient outcomes and could form the basis for standardized practice guidelines.
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Risk of relapse following COVID-19 or anty-SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorders (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_880;
Patients with NMOSD treated with immunosuppressants have a low risk of a relapse due to COVID-19 infection. In our study mRNA COVID-19 vaccines do not increase the risk of a relapse.
- Enspryng (satralizumab) / Roche
CIELO: A Randomized, Double-Blind, PlaceboControlled, Phase 3 Basket Study of Satralizumab in Patients with NMDAR- or LGI1-Antibody Encephalitis () - Oct 17, 2022 - Abstract #ANA2022ANA_661;
In our study mRNA COVID-19 vaccines do not increase the risk of a relapse. The CIELO study will provide efficacy, safety, PK, and PD data for satralizumab in participants with NMDAR and LGI1 AIE.
- Enspryng (satralizumab) / Roche
LUMINESCE: A Phase 3 Study Evaluating Satralizumab, a Therapeutic Recycling Antibody Targeting the IL-6 Receptor, in Patients with Generalized Myasthenia Gravis () - Oct 17, 2022 - Abstract #ANA2022ANA_496;
P3
LUMINESCE is the first study to assess inhibition of IL-6 signaling in gMG. LUMINESCE will assess the efficacy, safety, and PK/PD of satralizumab as an add-on therapy in a broad patient population with gMG.
- |||| Enspryng (satralizumab) / Roche
Enrollment open, Pan tumor: Cielo: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (clinicaltrials.gov) - Oct 12, 2022
P3, N=152, Recruiting, Sponsor: Hoffmann-La Roche
LUMINESCE will assess the efficacy, safety, and PK/PD of satralizumab as an add-on therapy in a broad patient population with gMG. Not yet recruiting --> Recruiting
- || Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Review, Journal: Immunobiology of neuromyelitis optica spectrum disorders. (Pubmed Central) - Sep 21, 2022
Acute relapses are treated with IV methylprednisolone or plasma exchange. Recent advances on the NMOSD immunobiology led to approved treatments such as eculizumab, satralizumab, and inebilizumab.
- | Enspryng (satralizumab) / Roche
Journal: Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment. (Pubmed Central) - Sep 20, 2022
In conclusion, interleukin-6 blocking may be effective against painful tonic seizures. This effect may be due to suppression of microglial activation and the resultant neuronal hyperexcitability.
- ||| Enspryng (satralizumab) / Roche
Trial primary completion date, Pan tumor: Cielo: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (clinicaltrials.gov) - Sep 14, 2022
P3, N=152, Not yet recruiting, Sponsor: Hoffmann-La Roche
This effect may be due to suppression of microglial activation and the resultant neuronal hyperexcitability. Trial primary completion date: Dec 2024 --> Jun 2025
- | olamkicept (FE999301) / Ferring, Enspryng (satralizumab) / Roche
Journal: Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder. (Pubmed Central) - Sep 10, 2022
Trial primary completion date: Dec 2024 --> Jun 2025 No abstract available
- | Enspryng (satralizumab) / Roche
Journal: Long-term safety of satralizumab in NMOSD. (Pubmed Central) - Sep 10, 2022
No abstract available No abstract available
- | Enspryng (satralizumab) / Roche, Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Journal: Genomic-Analysis-Oriented Drug Repurposing in the Search for Novel Antidepressants. (Pubmed Central) - Aug 27, 2022
In addition, we identified sarilumab and satralizumab as drugs that exhibit strong potential for use in the treatment of depression. Our findings indicate that a genomic-analysis-based approach can facilitate the discovery of drugs that can be repurposed for treating depression.
- | Journal: Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: A modeling analysis of literature aggregate data. (Pubmed Central) - Aug 22, 2022
Based on the construction of a time-course pharmacodynamic model, this study made a comprehensive quantitative comparison of seven drugs for the treatment of NMOSD for the first time. These results can not only serve as a quantitative supplement for the rational use of drugs in clinical practice but also provide a pharmacodynamic reference for clinical trial design and decision making in the future.
- Enspryng (satralizumab) / Roche
UMINESCE: Phase 3 study of satralizumab, a therapeutic recycling antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis (Poster area - Ballroom B1-B2) - Aug 20, 2022 - Abstract #WMS2022WMS_192;
P3
LUMINESCE is the first study to assess inhibition of IL-6 signalling in gMG. LUMINESCE will assess the efficacy, safety, and PK/PD of satralizumab as an add-on therapy in a broad patient population with gMG.
- |||||||| Enspryng (satralizumab) / Roche
New P3 trial, Pan tumor: Cielo: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (clinicaltrials.gov) - Aug 16, 2022
P3, N=152, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | olamkicept (FE999301) / Ferring
Journal: Olamkicept(sgp130Fc): The missing trial in Neuromyelitis optica spectrum disorder. (Pubmed Central) - Aug 11, 2022
Targeting IL-6 or IL-6 Receptor(like Satralizumab does) results in inhibition of both pro and anti-inflammatory pathways of IL-6. Sgp130FC(Olamkicept) is a monoclonal antibody that prevents only the proinflammatory pathway of IL-6 to be activated, and could represent a better way to target IL-6 pathway in Neuromyelitis optica spectrum disorder.